CARDIOTOXICITY OF SELECTIVE SEROTONIN RECAPTATION INHIBITORS: SYSTEMATIC REVIEW AND METANALYSIS

Authors

  • Luana Amaral Pedroso Universidade Federal de Ouro Preto
  • Nancy Scardua Binda
  • Flávia Silvia Corrêa Tomaz
  • Elza Conceição de Oliveira Sebastião
  • Andrea Grabe Guimarães

Abstract

Selective serotonin reuptake inhibitors (SSRIs) antidepressants are first-choice drugs to treat major depressive disorder. However, SSRIs have been associated with a heart rate variability (HRV) reduction, electrocardiogram (ECG) QT interval and QTc (QT corrected by heart rate) prolongation, and Torsades de Pointes (TdP), biomarkers of cardiotoxicity. To evaluate the influence of SSRIs on HRV and ECG intervals in humans. A systematic literature review was carried out in the MEDLINE (PubMed), Cochrane, Scopus and LILACS (BVS) databases, followed by a meta-analysis of the data of selected studies. The international methodological guidelines, Preferred Reporting Items for Systematic Reviews and Meta- Analyzes – PRISMA. PROSPERO registration number is CRD42022151097.Eleven studies were selected for the systematic review, and eight of these underwent quantitative analysis. It was evidenced that SSRIs are associated with increase of QTc interval (CI = 2.67 and 8.0), with no effects on HRV. QRS (CI = 0.00) and PR (CI = -0.01 – 0.01) intervals, and heart rate (CI = -5.93 – 2.7) were not altered. Considering the QTc interval as a predictor of cardiac arrhythmias and the results reviewed here, we concluded that QTc interval prolongation occurs Fluoxetine and Citalopram. No change of HRV or PR or QRS intervals was demonstrated.

Keywords: SSRI; antidepressants; QTc interval; heart rate variability; electrocardiogram

References

CARCELLER-SINDREU, M. et al. Lack of relationship between plasma levels of escitalopram and QTc-interval length. European Archives of Psychiatry and Clinical Neuroscience, v. 267, p. 815-822, 2017.

CARVALHO, A. F.; SHARMA, M. S.; BRUNONI, A. R.; VIETA, E.; FAVA, G.A. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom, v. 85, n. 5, p. 270-288, 2016.

CASTRO, V. M. et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ, v. 346, p. f288, 2013.

DARPO, B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. British Journal of Pharmacology, v. 159, n. 1, p. 49-57, 2010.

DRYE, L.T; et al. for the CitAD Research Group. Changes in QTc Interval in the Citalopram for Agitation in Alzheimer’s Disease (CitAD). Randomized Trial, v. 9, n. 6, p. e98426, 2014.

EDWARDS, J. G; GOLDIE, A.; PAPAYANNI-PAPASTHATIS, S. Effect of paroxetine on the electrocardiogram. Psychopharmacology, v. 97, p. 96-98, 1989.

FDA Drug Safety Communication. Abnormal Heart Rhythms Associated with High Doses of Celexa (Citalopram Hydrobromide). 2011 (online). Disponível em www.fda.gov/drugs/drugsafety/ucm269086.htm Acesso em: agosto, 2021.

FDA Drug Safety Communication. Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with High Doses. 2012 (online). Disponível em: www.fda. gov/drugs/drugsafety/ucm297391.htm Acesso em: agosto, 2021.

GUO, S.; CHEN, L.; CHENG, S.; XU, H. Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients - A network meta-analysis of randomized controlled trials. Medicine (Baltimore), v. 98, n. 22, p. e15786, 2019.

HEWER, W.; ROST, W., GATTAZ, W. F. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. European Archives of Psychiatry and Clinical Neuroscience, v. 246, n. 1, p. 1-6, 1995.

HIGGINS, J. P. T.; THOMPSON, S. G. Quantifying heterogeneity in a meta-analysis. Statist Med, v. 21, n. 11, p. 1539–58, 2002.

HU, M. X.; LAMERS, F.; PENNINX, B. W. J. H.; GEUS, E. J. C. Association between depression, anxiety and antidepressant use with T-wave amplitude and QT-interval. Front Neurosci, v. 12, p. 375, 2018.

ICH E14/S7B Implementation Working Group. Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential. Questions and Answers (R3), 2020. Disponível em: https://database.ich.org/sites/default/files/E14_Q%26As_R3_Q%26As.pdf Acesso em fevereiro, 2022.

JADAD A. R., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, v. 17, n. 1, p. 1-12, 1996.

KUHS, H.; RUDOLF, G. A. E. Cardiovascular effects of paroxetine. Psychopharmacology, v. 102, p. 379-382, 1990.

LONEY, P. L., CHAMBERS, L. W., BENNETT, K. J., ROBERTS, J. G., STRATFORD, P. W. Critical appraisal of the health research literature: Prevalence or incidence of a health problem. Chronic Diseases in Canada, v. 19, n. 4, p. 170-176, 1998.

LOPES, P. F. F. et al. Aplicabilidade Clínica da Variabilidade da Frequência Cardíaca. Rev Neurocienc, v. 21, n. 4, p. 600-60, 2013.

OJERO-SENARD, A. et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl), v. 234, n. 20, p. 3075-3081, 2017.

POHL, R.; BALON, R.; JAYARAMAN, A.; DOLL, R.G.; YERAGANI, V. Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. Journal of Psychosomatic Research, v. 55, n. 3, p. 247-251, 2003.

RODRIGUEZ DE LA TORRE, B. et al. Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients. Therapeutic Drug Monitoring, 2001; v.23, n. 4, p. 435-40.

SHAMSEER L, et al. the PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, v .349, p. g7647, 2015.

STOCKBRIDGE, N.; MORGANROTH, J.; SHAH, R. R.; GARNETT, C. Dealing with Global Safety Issues - Was the Response to QT-Liability of Non-Cardiac Drugs Well Coordinated? Drug Saf, v. 36, p. 167–182, 2013.

STONER, S.C. Management of serious cardiac adverse effecs of antipsychotic medications. Ment Health Clin, v. 7, n. 6, p. 246-54, 2017.

STRIK, J. J. M. H.; HONIG, A.; LOUSBERG, R.; CHERIEX, E. C.; VAN PRAAG, H. M. Cardiac side-effects of two selective serotonina reuptake inhibitors in middle-age and elderly depressed patients. International Clinical Psychopharmacology, v. 13, p. 263-267, 1998.

THE CREDBLEMEDS. QTDrugs list. Disponível em: < https://crediblemeds.org/index.php/login/dlcheck> Acesso em: janeiro/2022.

TISDALE J. E. et al. American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation, v. 142, n. 15 p. e214-e233, 2020.

UPWARD, J. W.; EDWARDS, J. G.; GOLDIE, A.; WALLER, D. G. Comparative effects of fluoxetine and amitriptyline on cardiac function. British Journal of Clinical Pharmacology, v. 26, p. 399-402, 1988.

WARING, W. S. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug, Healthcare and Patient Safety, v. 4, p. 93-101, 2012.

WELLS, G.A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomizedstudies in meta-analyses (2013). Acesso em: 29/06/2020.Disponível em: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

YERAGANI, V.K.; JAMPALA, V.C.; SOBELEWSKI, E.; KAY, J.; IGEL, G. Effects of Paroxetine on Heart Period Variability in Patients with Panic Disorder: A Study of Holter ECG Records. Neuropsychobiology, v. 40, p. 124-128, 1999.

Downloads

Published

2023-08-02

How to Cite

Amaral Pedroso, L., Scardua Binda, N., Silvia Corrêa Tomaz, F., Conceição de Oliveira Sebastião, E., & Grabe Guimarães, A. (2023). CARDIOTOXICITY OF SELECTIVE SEROTONIN RECAPTATION INHIBITORS: SYSTEMATIC REVIEW AND METANALYSIS. REVISTA CIENTÍFICA DA FAMINAS, 18(1), 30–41. Retrieved from https://periodicos.faminas.edu.br/index.php/RCFaminas/article/view/714

Issue

Vol. 18 No. 1 (2023): REVISTA CIENTÍFICA DA FAMINAS

Section

Revisão

License

Copyright (c) 2023 REVISTA CIENTÍFICA DA FAMINAS

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Autores que publicam nesta revista concordam com os seguintes termos:

  1. Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
  2. Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
  3. Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).